|
Therapeutic plasmapheresis in myasthenic crisis after botox injection
|
A. Chegini   |
|
|
| Keywords: Key words: Blood Component Removal, Myasthenia Gravis, Botulinum Toxins |
|
|
Full-Text [PDF 189 kb]
(3531 Downloads)
| Abstract (HTML) (6214 Views)
|
Type of Study: case report |
Subject:
Blood transfusion medicine
Published: 2016/01/6
|
|
|
|
|
|
|
Full-Text: (17694 Views) |
References :
- Pinching AJ, Peters DK. Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2(8000): 1373-6.
- Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th ed. New York: McGraw-Hill Education; 2015. p. 2704-6.
- MCLeod BC, Weinstein R ,Winters JL. Textbook of apheresis principles and practice. 3rd ed. USA: AABB; 2010. p. 295-317.
- King Karen E, Bandarenko N. Blood Transfusion therapy (a physician's handbook). 11th ed. USA: AABB; 2014. p. 217-24.
- Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the apheresis applications committee of the American society for apheresis . J Clin Apher 2007; 22(3): 75-106.
- Roback DJ, Combs MR, Grossman BJ, Hillyer Ch. Technical Manual. 6th ed. USA: AABB. p. 697-711.
- Klein HG, Anstee DJ. Mollison’s Blood Transfusion in Clinical Medicine. 12th ed. 2014. p. 782-3.
- Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol 2010; 55(1): 8-14.
- Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol 1999; 38(9): 641-55.
- Giotzolou T, Cordivari C, Lee PJ, Hanna MG, Lees AJ. Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature. J Nourol Neurosurg Psychiatry 2005; 76(11): 1594-6.
- Patel V, Elston J, Malhotra R. Prolonged effect of botulinum toxin-A treatment in patients with Myastheina Gravis. Journal of Clinical & Experimental Ophthalmology 2011; 2: 3.
- Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61(12): 1652-61
- Romi F, Gihus NE, Aarli JA. Myasthenia gravis: clinical, immunological and therapeutic advances.
Acta Neurol Scand 2005; 111(2): 134-41
- Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2(10): 797-804.
- Richman DP, Wollmann RL, Maselli RA, Gomez CM, Corey AL, Agius MA, et al. Effector mechanisms of myasthenic antibodies. Ann N Y Acad Sci 1987; 681: 264-73.
- Lindstrom JM, Seybold ME, Lenon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976 ;26(11): 1054-9.
- Seybold ME. Plasmapheresis in myasthenia gravis. Ann NY Acad Sci 1987; 505: 584-7
- Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppression drug therapy in myasthenia gravis. N Engl J Med 1977; 297(21): 1134-40
- Dau PC. Plasmapheresis therapy in Myasthenia gravis. Muscle Nerve 1980; 3(6): 468-82.
- Szczepiokowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of American Society for Apheresis. J Clin Apher 2010; 25(3): 83-177
- Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IK, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13(7): 691-9.
- Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol 1994; 97 Suppl 1: 49-51.
- Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997; 41(6): 789-96.
- Qureshi AI, Chodhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al. Plasma exchange versus in intravenous immunoglobulin treatment in myasthenia crisis. Neurology 1999; 52(3): 629-52.
|
|
|
|
|
|
Sci J Iran Blood Transfus Organ 2016; 12(4): 388-393
|
|
|
|
|
|
Therapeutic plasmapheresis in myasthenic
crisis after botox injection
Chegini A.1
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Abstract
Background and Objectives
Botox decreases wrinkles in face and chin. This drug minimizes muscle activity with its side effects being rare. This article presents one of this rare cases.
Case
A 30-year-old woman with petosis, diplopia, dysartheria, dysphagia and muscle weakness was admitted to the hospital. She had no history of disease. She had three Botox injections during the preceding month. In the examination, muscle weakness 4/5 (cervical extensor, ocular and pharynx) was detected. Her diagnosis was myasthenia gravis. With TPE, force enhancement after muscle stretch was seen and she was separated from artificial ventilation.
Conclusions
Myasthenia gravis is caused by antibody-acetylcholine receptor at the neuromuscular junction or motor end plate. Therapeutic plasmapheresis decreases the level of antibody-acetylcholine receptor.
Key words: Blood Component Removal, Myasthenia Gravis, Botulinum Toxins
Received: 11 Jul 2014
Accepted: 24 Jun 2015
Correspondence: Chegini A., MD. Specialist in Anesthesiology. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052256; Fax: (+9821) 88601599
E-mail: a.chegini@ibto.ir
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
|
.jpg)
.png)
